BFM
APGE icon

Boothbay Fund Management’s Apogee Therapeutics APGE Stock Holding History

Boothbay Fund Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-85,183
Closed -$3.7M – 1855
2025
Q2 		$3.7M Buy
+85,183
New +$3.24M 0.07% 360

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Boothbay Fund Management's APGE Position: Q3 2025 in Review

Boothbay Fund Management sold out of Apogee Therapeutics (APGE) in Q3 2025, closing a stake of 85,183 shares — an estimated $3.7M sold.

Boothbay Fund Management first reported a position in APGE in Q2 2025 and held it in 1 quarter. The position peaked at $3.7M in Q2 2025. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • Boothbay Fund Management reported no remaining Apogee Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 85,183 Apogee Therapeutics shares in Q3 2025, an estimated $3.7M.
  • Boothbay Fund Management first reported a position in Apogee Therapeutics in Q2 2025 and held it in 1 quarter.
  • Boothbay Fund Management's Apogee Therapeutics position peaked at $3.7M in Q2 2025.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.